Ferronova Pty Ltd.

Ferronova Pty Ltd. , based in Australia, develops innovative surgical oncology tracer systems designed to enhance cancer treatment and staging, particularly for complex cancers like gastric and esophageal cancers. Ferronova Pty Ltd is dedicated to advancing surgical oncology through its development of specialized tracer systems. Founded in 2016 and headquartered in Adelaide, Australia, the company has secured a total of AUD 7.

993 mn through various funding rounds, with its most recent funding of AUD 3. 000 mn coming from a grant provided by the Government of South Australia in January 2023. The company has completed 6 deals since its inception, focusing on delivering solutions that improve cancer treatment outcomes. Ferronova specializes in innovative surgical oncology tracer systems designed to enhance the treatment guidance and staging of complex cancers, particularly upper gastrointestinal cancers such as gastric and esophageal cancers.

The flagship product, FerroTrace®, is a mannose-labelled iron-oxide nanoparticle that facilitates the accurate detection of high-risk lymph nodes and early identification of metastatic spread. By improving the mapping of the lymphatic network, FerroTrace® aids surgeons in making informed clinical decisions during procedures, ultimately aiming to increase patient survival rates. This technology can be utilized before, during, and after surgery and is designed to work in conjunction with infrared dyes for enhanced intra-operative visualization. Ferronova's products are primarily targeted at healthcare providers in regions with high cancer prevalence, including North America, Europe, and parts of Asia, where advanced surgical oncology treatments are in demand.

Ferronova operates on a business model that emphasizes partnerships with medical institutions and clinical settings, resulting in a direct-to-consumer structure where products like FerroTrace® are utilized in surgical procedures. Revenue is generated through the sale of FerroTrace® and potentially other future products under development, primarily through contracts with hospitals and surgical centers engaged in oncology treatments. The transactions typically involve bulk orders for the nanoparticles, which are supplied to healthcare providers for use in surgeries aimed at improving cancer treatment outcomes. Given the specificity and advanced technology of FerroTrace®, pricing structures are expected to reflect the premium nature of the product, aligning with the healthcare industry's standards for specialized medical devices.

Ferronova intends to leverage its recent funding of AUD 3. 000 mn to accelerate product commercialization and expand its market presence. The company is looking to introduce new products addressing unmet needs in surgical oncology and plans for geographic expansion into markets with high cancer prevalence, particularly in North America and Europe, by 2024. The funding will support these initiatives, enabling Ferronova to enhance product offerings and reach a broader customer base.

In December 2025, Ferronova Pty Ltd. raised USD 6 million in venture funding led by returning investor Uniseed, with participation from other returning investors Artesian and Renew Pharmaceuticals Limited. The company will use the December 2025 funding to support its expansion plans initiatives.